GlassScriptPhysician profile
Thomas Yunger
NPI 1962496844
$352,959.74
in general payments reported to CMS, 2019-2025
40 companies · $27K in 2025
The $27K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99K · 2020: $63K · 2021: $15K · 2022: $32K · 2023: $73K · 2024: $44K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $129K · Food and Beverage: $9,915 · Travel and Lodging: $5,302 · Education: $98.24 · Gift: $17.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $129,025.00 |
| Food and Beverage | $9,915.29 |
| Travel and Lodging | $5,301.57 |
| Education | $98.24 |
| Gift | $17.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $336,601.56 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,877.95 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Astrazeneca Pharmaceuticals LP | $2,803.95 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Grifols USA, LLC | $1,102.49 | 2019-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $891.08 | 2019-2025 | Dupixent |
| Genzyme Corporation | $872.73 | 2019-2025 | |
| Genentech USA, INC. | $819.49 | 2019-2025 | Xolair, Esbriet |
| Actelion Pharmaceuticals US, INC. | $677.05 | 2019-2023 | Opsumit |
| Viiv Healthcare Company | $600.00 | 2019 | |
| Inspire Medical Systems, INC. | $554.89 | 2023-2025 | Inspire |
| Merck Sharp & Dohme LLC | $414.71 | 2019-2024 | Zerbaxa, Recarbrio |
| Takeda Pharmaceuticals U.S.A., INC. | $376.71 | 2020-2025 | Glassia |
| United Therapeutics Corporation | $336.59 | 2019-2024 | Tyvaso |
| Axsome Therapeutics, INC. | $304.59 | 2023-2025 | Sunosi |
| Jazz Pharmaceuticals INC. | $204.84 | 2019-2024 | Xywav |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $188.91 | 2021-2025 | Tezspire |
| Pulmonx Corporation | $185.44 | 2021-2025 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Insmed, INC. | $137.91 | 2019-2025 | Arikayce |
| Mylan Specialty L.P. | $130.65 | 2019-2024 | Yupelri |
| Baxter Healthcare | $121.38 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Teva Pharmaceuticals USA, INC. | $117.44 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $105.82 | 2020-2023 | |
| Lilly USA, LLC | $89.98 | 2025 | Zepbound |
| Gilead Sciences, INC. | $70.87 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $63.92 | 2019-2023 | |
| Kaleo, INC. | $46.50 | 2021-2022 | |
| Verona Pharma, INC. | $42.77 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $31.44 | 2025 | Yupelri |
| Shire North American Group INC | $25.42 | 2019 | |
| Astellas Pharma US INC | $23.22 | 2022 | |
| Shionogi INC | $21.59 | 2022 | |
| Mallinckrodt Enterprises LLC | $20.65 | 2019 | |
| Allergan, INC. | $15.25 | 2019 | |
| Philips North America LLC | $14.92 | 2024 | (Ak6) Vest Therapy |
| Intercept Pharmaceuticals, INC. | $14.44 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.62 | 2019 | |
| Paratek Pharmaceuticals, INC. | $13.24 | 2020 | |
| Chiesi USA, INC. | $13.24 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.49 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Yunger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.